Switching to a focus on earlier stage disease, the phase III INDIGO trial is randomizing IDH1/2mt residual or recurrent grade 2, nonenhancing glioma to receive vorasidenib or placebo, with primary endpoint of PFS (38). Here, IDH1 is linked to central nervous system cancer.